Brazil Cancer Drug Market Overview, 2031

The adoption of cancer drugs in Brazil is influenced by several regulatory, economic, and healthcare system challenges that affect the speed at which innovative therapies become accessible to patients. One of the key barriers lies in the regulatory and reimbursement process managed by the Brazilian Health Regulatory Agency (ANVISA) and the National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC). While ANVISA is responsible for approving new oncology drugs, additional evaluations are required before these therapies are incorporated into the public healthcare system, known as the Sistema Único de Saúde (SUS). This process often involves cost-effectiveness assessments and budget impact analyses, which can delay widespread adoption of high-cost targeted therapies and immunotherapies. Financial constraints within the public healthcare system further limit the rapid expansion of innovative treatments, particularly because a large portion of the population relies on publicly funded healthcare services. Infrastructure disparities also present challenges. Although major urban hospitals in cities such as São Paulo and Rio de Janeiro have advanced oncology departments and diagnostic capabilities, many regional hospitals lack specialized infusion units, molecular diagnostic laboratories, and trained oncology professionals needed to administer complex biologic therapies. Workforce shortages, particularly in oncology specialists and oncology-trained nurses, can slow the implementation of new treatment protocols. Additionally, compliance requirements, pharmacovigilance monitoring, and administrative procedures related to drug procurement and distribution create further operational complexity. Integrating advanced therapies into existing hospital systems often requires staff training, new diagnostic capabilities, and updated treatment guidelines. These factors collectively create a gradual adoption environment in which innovative cancer drugs are typically introduced first in private healthcare institutions and major oncology centers before expanding to the broader public healthcare system.

According to the research report, "Brazil Cancer Drug Market Outlook, 2031," published by Bonafide Research, the Brazil Cancer Drug market is anticipated to grow at more than 9.92% CAGR from 2026 to 2031. Cancer drug adoption in Brazil accelerates when regulatory approval, reimbursement support, and the capabilities of large oncology centers align with patient demand. The private healthcare sector plays a significant role in the early adoption of innovative cancer treatments, as private hospitals and oncology clinics often have greater financial flexibility and faster access to newly approved therapies. These institutions typically possess advanced diagnostic infrastructure, including molecular testing laboratories and specialized oncology units capable of administering targeted therapies and immunotherapies. Once therapies demonstrate strong clinical benefits and receive approval for reimbursement under the public healthcare system, adoption expands to public hospitals and cancer treatment facilities serving a broader population. Brazil’s network of specialized oncology institutions, including cancer research centers and university hospitals, also contributes to the adoption of innovative therapies through participation in international clinical trials. These research collaborations allow physicians to gain early experience with new drugs and treatment protocols before they are widely commercialized. National cancer control programs and government initiatives aimed at improving oncology care are gradually strengthening diagnostic capabilities and treatment infrastructure across the country. As biomarker testing becomes more accessible, targeted therapies are increasingly incorporated into treatment strategies for cancers such as lung, breast, and colorectal cancer. The interaction between private healthcare innovation, public healthcare expansion, and growing clinical research activity creates a dual adoption pathway where new therapies are first implemented in specialized centers and private hospitals before gradually reaching a wider patient population across the healthcare system.

Cancer treatment in Brazil includes a variety of therapeutic approaches such as chemotherapy, targeted therapies, immunotherapies, hormonal treatments, and emerging combination regimens. Chemotherapy remains the most widely used treatment modality due to its relatively lower cost and broad availability across both public and private healthcare facilities. It continues to play a central role in treating common cancers such as breast, lung, colorectal, and cervical cancer. However, the oncology landscape in Brazil is gradually evolving with the increasing use of targeted therapies designed to attack specific molecular pathways associated with tumor growth. Drugs such as tyrosine kinase inhibitors and monoclonal antibodies are becoming more common in specialized oncology centers where molecular diagnostic testing is available. Immunotherapy has also emerged as an important treatment option, particularly immune checkpoint inhibitors used in cancers such as melanoma, lung cancer, and certain hematologic malignancies. These therapies stimulate the body’s immune system to recognize and destroy cancer cells and have demonstrated promising clinical outcomes for selected patient populations. Hormonal therapies remain widely used for hormone-sensitive cancers such as breast and prostate cancer and are often combined with other treatments to improve therapeutic effectiveness. In addition, emerging therapies such as antibody-drug conjugates and advanced cellular therapies are gradually being introduced in leading oncology institutions. Treatment decisions are typically guided by multidisciplinary tumor boards that evaluate tumor biology, disease stage, and patient characteristics to determine the most appropriate therapy. This combination of traditional chemotherapy and advanced precision therapies reflects Brazil’s evolving oncology treatment landscape.

The demand for cancer drugs in Brazil is influenced by the prevalence of several major cancer types and the complexity of their treatment protocols. Breast cancer represents one of the largest segments of oncology treatment in the country, with therapies including chemotherapy, hormonal therapy, targeted drugs, and immunotherapies depending on tumor subtype and receptor expression. Lung cancer is another major indication driving demand for oncology drugs, particularly non-small cell lung cancer where targeted therapies and immunotherapies have become increasingly important treatment options. Colorectal cancer also contributes significantly to oncology drug consumption and is often treated using a combination of chemotherapy and targeted biologic therapies. Prostate cancer remains the most frequently diagnosed cancer among men in Brazil and is primarily managed using hormonal therapy, although chemotherapy and targeted drugs may be used in advanced stages of the disease. Hematologic malignancies including leukemia, lymphoma, and multiple myeloma require specialized treatment regimens involving biologics, immunotherapies, and combination therapies administered in advanced oncology centers. Other cancers such as cervical cancer, gastric cancer, liver cancer, kidney cancer, ovarian cancer, bladder cancer, thyroid cancer, brain tumors, and skin cancer also contribute to the overall demand for oncology drugs. National cancer screening programs and public health initiatives aimed at early detection are gradually improving diagnosis rates and influencing treatment demand. Clinical guidelines issued by Brazilian oncology associations help ensure standardized and evidence-based treatment practices across different cancer indications.

Cancer drugs in Brazil are administered primarily through injectable and oral routes, both of which play important roles in oncology treatment. Injectable therapies dominate chemotherapy, immunotherapy, and many biologic treatments and are typically administered in hospital oncology departments or specialized infusion clinics. These facilities provide a controlled environment where healthcare professionals can monitor patients during treatment and manage potential side effects associated with complex drug regimens. Hospitals often maintain dedicated chemotherapy preparation units staffed with oncology pharmacists and trained nurses responsible for compounding and administering intravenous medications. Oral therapies have become increasingly important with the development of targeted small-molecule inhibitors and hormonal treatments that patients can take outside hospital settings. These medications provide greater convenience for patients and reduce the need for frequent hospital visits, particularly for individuals undergoing long-term treatment. However, oral therapies require careful monitoring to ensure adherence and to manage potential adverse reactions. Physicians, pharmacists, and healthcare teams often collaborate to provide patient education and follow-up support. The ability to combine injectable and oral therapies allows oncologists to design individualized treatment strategies tailored to the patient’s cancer type, disease stage, and overall health condition. Injectable therapies remain essential for aggressive cancers requiring intensive treatment protocols, while oral medications are commonly used for maintenance therapy and long-term disease management.



The distribution of cancer drugs in Brazil is supported by a multi-layered pharmaceutical supply chain involving hospital pharmacies, retail pharmacies, and specialized pharmaceutical distributors. Hospital pharmacies play a central role in handling injectable oncology drugs such as chemotherapy agents, biologics, and immunotherapies. These pharmacies operate within hospitals and cancer treatment centers where pharmacists prepare medications under strict sterile conditions and ensure accurate dosing. Large oncology hospitals and specialized cancer institutes often maintain dedicated pharmacy units capable of managing complex biologic therapies and high-value drugs. Retail pharmacies are primarily responsible for dispensing oral cancer medications and supportive treatments used to manage therapy-related side effects. Pharmacists in these settings provide counseling and help monitor patient adherence to long-term treatment regimens. Pharmaceutical wholesalers and logistics providers ensure efficient distribution of oncology drugs across healthcare facilities while maintaining strict cold-chain conditions required for temperature-sensitive biologic products. In addition, government procurement programs support the supply of oncology medicines to public hospitals within the SUS healthcare system. Digital prescription systems and hospital procurement networks further improve coordination between healthcare providers and pharmacies. This integrated distribution system ensures that both conventional chemotherapy medicines and advanced targeted therapies reach patients safely and efficiently while maintaining high standards of pharmaceutical quality and regulatory compliance.
Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Other Treatment Types
By Indication
• Breast Cancer
• Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
• Colorectal Cancer
• Prostate Cancer
• Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
• cervical cancer
• Stomach/ Gastric Cancer
• Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies / Drug Stores
• Online Pharmacies